Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates.

Details

Ressource 1Download: serval:BIB_4530AD7CB6B4.P001 (354.51 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_4530AD7CB6B4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates.
Journal
International Journal of Public Health
Author(s)
Berchtold André, Michaud Pierre-André, Nardelli Haefliger Denise, Suris Joan-Carles
ISSN
1661-8564[electronic], 1661-8556[linking]
Publication state
Published
Issued date
2010
Peer-reviewed
Oui
Volume
55
Number
1
Pages
25-34
Language
english
Abstract
OBJECTIVES: Human papillomavirus (HPV) is a sexually transmitted infection of particular interest because of its high prevalence rate and strong causal association with cervical cancer. Two prophylactic vaccines have been developed and different countries have made or will soon make recommendations for the vaccination of girls. Even if there is a consensus to recommend a vaccination before the beginning of sexual activity, there are, however, large discrepancies between countries concerning the perceived usefulness of a catch-up procedure and of boosters. The main objective of this article is to simulate the impact on different vaccination policies upon the mid- and long-term HPV 16/18 age-specific infection rates. METHODS: We developed an epidemiological model based on the susceptible-infective-recovered approach using Swiss data. The mid- and long-term impact of different vaccination scenarios was then compared. RESULTS: The generalization of a catch-up procedure is always beneficial, whatever its extent. Moreover, pending on the length of the protection offered by the vaccine, boosters will also be very useful. CONCLUSIONS: To be really effective, a vaccination campaign against HPV infection should at least include a catch-up to early reach a drop in HPV 16/18 prevalence, and maybe boosters. Otherwise, the protection insured for women in their 20s could be lower than expected, resulting in higher risks to later develop cervical cancer.
Pubmed
Web of science
Open Access
Yes
Create date
30/12/2009 11:58
Last modification date
01/10/2019 7:17
Usage data